Clinical Trial Update: Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating the immunogenicity and safety of NmCV-5, a pentavalent meningococcal vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• NmCV-5

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Meningococcal Meningitis | Phase 3 | Status: COMPLETED